Valentin Goutaudier, Marta Sablik, Maud Racapé, Olivia Rousseau, Benoit Audry, Nassim Kamar, Marc Raynaud, Olivier Aubert, Béatrice Charreau, Emmanuelle Papuchon, Richard Danger, Laurence Letertre, Lionel Couzi, Emmanuel Morelon, Moglie Le Quintrec, Jean-Luc Taupin, Eric Vicaut, Christophe Legendre, Hoa Le Mai, Vishnu Potluri, Thi-Van-Ha Nguyen, Marie-Eliane Azoury, Alice Pinheiro, Georges Nouadje, Pierre Sonigo, Dany Anglicheau, Ineke Tieken, Serge Vogelaar, Christian Jacquelinet, Peter Reese, Pierre-Antoine Gourraud, Sophie Brouard, Carmen Lefaucheur, Alexandre Loupy
There is an unmet need for robust and clinically validated biomarkers of kidney allograft rejection. Here we present the KTD-Innov study (ClinicalTrials.gov, NCT03582436), an unselected deeply phenotyped cohort of kidney transplant recipients with a holistic approach to validate the clinical utility of precision diagnostic biomarkers. In 2018-2019, we prospectively enrolled consecutive adult patients who received a kidney allograft at seven French centers and followed them for a year. We performed multimodal phenotyping at follow-up visits, by collecting clinical, biological, immunological, and histological parameters, and analyzing a panel of 147 blood, urinary and kidney tissue biomarkers...
April 16, 2024: European Journal of Epidemiology